Regulation E. No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) no 726/2004. Off J Eur Union 2007; 324: 121-37.

High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455–64.

Article  CAS  PubMed  Google Scholar 

Precedence Research. Cell and Gene Therapy Market Size to Surpass USD 93.78 BN by 2030. 2022. https://www.globenewswire.com/en/news-release/2022/11/30/2564827/0/en/Cell-and-Gene-Therapy-Market-Size-to-Surpass-USD-93-78-BN-by-2030.html.

EU. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Off J Eur Union. 2009;242:3–12.

Google Scholar 

O’Connor TP, Crystal RG. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet. 2006;7:261–76.

Article  PubMed  Google Scholar 

Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–60.

Article  CAS  PubMed  Google Scholar 

McCormack MP, Rabbitts TH. Activation of the T-Cell Oncogene LMO2 after Gene Therapy for X-Linked Severe Combined Immunodeficiency. N Engl J Med. 2004;350:913–22.

Article  CAS  PubMed  Google Scholar 

Gene therapy needs a long-term approach. Nat Med .2021; 27: 563-563.

Aiman W, Kazmi SH, Saeed M, Khan MI, Omar Z, Suleman M, et al. Efficacy and safety of viral vector based gene therapy in patients with hemophilia a: a systematic review. Blood. 2022;140:12992–3.

Article  Google Scholar 

U.S. Food and Drug Administration. Breakthrough Therapy 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy.

European Medicines Agency. PRIME: priority medicines. https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines.

Pharmaceuticals and Medical Devices Agency. Pioneering Drug Designation System (Sakigake Designation System). https://www.pmda.go.jp/review-services/drug-reviews/0002.html.

Ministry of Food and Drug Safety. Global Innovative products on Fast Track designation. https://www.mfds.go.kr/wpge/m_1113/de080101l0001.do.

Purja S, Shin H, Lee J-Y, Kim E. Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis. Arch Pharm Res. 2021;44:725–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Purja S, Oh S, Kim E. A Systematic Review on Neurological Aspects of COVID-19: Exploring the Relationship Between COVID-19-Related Olfactory Dysfunction and Neuroinvasion. Front Neurol. 2022;13:887164.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. COVID-19 vaccines: development, evaluation, approval and monitoring. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring#accelerated-evaluation.

Jokura Y, Yano K, Yamato M. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union. J Tissue Eng Regen Med. 2018;12:e1056–e1062.

Article  CAS  PubMed  Google Scholar 

Nagai S. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. Int J Mol Sci. 2019;20:3801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iglesias-Lopez C, Obach M, Vallano A, Agustí A. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy. 2021;23:261–74.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. Guidance for Industy: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions.

U.S. Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.

U.S. Food and Drug Administration. Fast Track 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.

U.S. Food and Drug Administration. Accelerated Approval. 2023. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval.

U.S. Food and Drug Administration. Priority Review. 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy designation. 2023. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation.

European Medicines Agency. Human regulatory: Support for early access. https://www.ema.europa.eu/en/human-regulatory/overview/support-early-access.

European Medicines Agency. Accelerated Assessment. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment.

European Medicines Agency. Conditional marketing authorization. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation.

Ministry of Health, Labour and Welfare. Handling of priority review examination, etc. 2020. https://www.mhlw.go.jp/web/t_doc?dataId=00tc5289&dataType=1&pageNo=1.

Ministry of Health, Labour and Welfare. Designation System for Pioneering Medical Devices, In-Vitro Diagnostics, and Regenerative Medicine Products. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/000013196.html.

Pharmaceuticals and Medical Devices Agency. Reviews: Regenerative Medical Products Reviews. https://www.pmda.go.jp/english/review-services/reviews/0001.html.

Ministry of Health, Labour and Welfare. Handling of conditional approval of pharmaceuticals. 2020. https://www.mhlw.go.jp/web/t_doc?dataId=00tc5290&dataType=1&pageNo=1.

Korean Law Translation Center. Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products. 2020. https://elaw.klri.re.kr/kor_service/lawView.do?hseq=56486&lang=ENG.

U.S. Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products.

Code of Federal Regulations. 21 C.F.R. PART 316-ORPHAN DRUGS https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316.

U.S. Food and Drug Administration. ORPHAN DRUG MODERNIZATION PLAN. 2018. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-modernization-plan.

European Medicines Agency. Orphan designation: Overview. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview.

EU. REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products. Off J Eur Communities 2000.

Ministry of Health, Labour and Welfare. Overview of Orphan Drug/Medical Device Designation System. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html.

Japanese Law Translation. Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. 2015. https://www.japaneselawtranslation.go.jp/ja/laws/view/3213.

Ministry of Food and Drug Safety. Regulations on Designation of Orphan Drugs. 2018. https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71453&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2.

Korean Law Translation Center. Rare Disease Management Act. 2019. https://elaw.klri.re.kr/kor_service/lawView.do?hseq=50746&lang=ENG.

U.S. Food and Drug Administration. Frequently Asked Questions: Breakthrough Therapies. 2022. https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies.

European Medicines Agency. Pre-authorisation guidance. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance.

Mikami K Regulatory Updates-Facilitating Early Patients Access. https://www.pmda.go.jp/files/000236029.pdf.

U.S. Food and Drug Administration. Frequently Asked Questions (FAQ) About Designating an Orphan Product. 2019. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/frequently-asked-questions-faq-about-designating-orphan-product.

American Society of Gene & Cell Therapy. Q4 2022 Quarterly Data Report: Gene, Cell, & RNA Therapy Landscape. https://asgct.org/global/documents/asgct_citeline-q4-2022-report_final.aspx.

U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.

European Medicines Agency. Medicines: European public assessment reports (EPAR). https://www.ema.europa.eu/en/medicines/ema_group_types/ema_medicine.

Pharmaceuticals and Medical Devices Agency. Review Reports: Regenerative Medical Products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html.

Pharmaceuticals and Medical Devices Agency. Information search for regenerative medicine products. https://www.pmda.go.jp/PmdaSearch/saiseiSearch/.

Ministry of Food and Drug Safety. Drug Approval Report. https://www.mfds.go.kr/eng/brd/m_19/list.do.

American Society of Gene & Cell Therapy. Q1 2023 Quarterly Data Report: Gene, Cell, & RNA Therapy Landscape. 2023. https://asgct.org/global/documents/asgct-citeline-q1-2023-report.aspx.

European Medicines Agency. Orphan incentives. https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives.

Ministry of Food and Drug Safety. Major Content of Lower Statute of “ACT ON THE SAFETY OF AND SUPPORT FOR ADVANCED REGENERATIVE MEDICINE AND ADVANCED BIOPHARMACEUTICALS”. 2020. https://www.mfds.go.kr/eng/brd/m_75/view.do?seq=18&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1.

Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324.

Article  CAS  PubMed  Google Scholar 

Brown DG, Wobst HJ, Kapoor A, Kenna LA, Southall N. Clinical development times for innovative drugs. Nat Rev Drug Discov. 2022;21:793–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. European Medicines Agency Guidance for applicants seeking access to PRIME scheme 2023. https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-applicants-seeking-access-prime-scheme_en.pdf.

ICH Expert Working Group. ICH HARMONISED GUIDELINE E17: GENERAL PRINCIPLES FOR PLANNING AND DESIGN OF MULTI-REGIONAL CLINICAL TRIALS 2017. https://database.ich.org/sites/default/files/E17EWG_Step4_2017_1116.pdf.

Korean Law Information Center. Rules on Advanced Biopharmaceutical Safety and Support. 2020. https://www.law.go.kr/lsSc.do?menuId=1&subMenuId=15&tabMenuId=81&query=%EC%B2%A8%EB%8B%A8%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88#undefined.

Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. Jama Intern Med. 2014;174:90–5.

Article  PubMed  Google Scholar 

Banzi R, Gerardi C, Bertele V, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. 2015;26:572–84.

Article  PubMed  Google Scholar 

Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. Jama. 2010;304:2172–3.

Article  CAS  PubMed  Google Scholar